Skip to content

Advertisement

  • Research article
  • Open Access

SP, CGRP changes in pyridoxine induced neuropathic dogs with nerve growth factor gene therapy

  • †1,
  • †2,
  • 3,
  • 4,
  • 4,
  • 3,
  • 5,
  • 6,
  • 2Email author and
  • 1Email author
†Contributed equally
BMC Neuroscience201617:1

https://doi.org/10.1186/s12868-015-0236-5

©  Kang et al. 2016

  • Received: 8 November 2015
  • Accepted: 23 December 2015
  • Published:

Abstract

Background

Nerve growth factor (NGF) is known not only as a major factor for neuronal plasticity but also as a pain stimulator. Although there have been several trials with NGF for its application in the regeneration or protection of the nervous system, the pain induced by NGF remains a challenge to be overcome. In this study, the pain induced by NGF gene therapy was evaluated.

Results

Vehicle or recombinant dog NGF plasmid was administered into the intrathecal space of dogs. Twenty-four hours after the vehicle or NGF plasmid inoculation, dogs were subcutaneously treated with 150 mg/kg pyridoxine every day for 7 days. For pain assessment, physical examination and electrophysiological recording were performed. Only in the vehicle-treated group, weight loss occurred, while NGF plasmid inoculation significantly improved this physical abnormalities. In the vehicle-treated group, electrophysiological recordings showed that H-reflex disappeared at 24 h after the last pyridoxine treatment. However, in the NGF plasmid inoculated group, the H-reflex were normal. In the results of immunohistochemistry, the NGF plasmid administration efficiently expressed in the dorsal root ganglia and significantly increased the pyridoxine-induced reduction of calcitonin gene-related peptide (CGRP) immunoreactive neurons, but not in substance P immunoreactive neurons, in the dorsal root ganglia.

Conclusions

Given these results, we reason that NGF gene therapy in pyridoxine induced neuropathic dogs does not induce neuropathic pain with this dosage, even with increasing the expression of CGRP.

Keywords

  • Calcitonin gene-related peptide
  • Dog
  • H reflex
  • Nerve growth factor
  • Pyridoxine
  • Neuropathy

Background

Neurotrophic factors are undoubted stimulators for the outgrowth of specific neuronal populations [1, 2]. Due to their potency, neurotrophic factors have drawn high expectations from scientists and various trials have attempted to investigate their efficacy [1]. Among the various neurotrophic factors, nerve growth factor (NGF) was the first neurotrophic factor discovered [3] and it was revealed that it impacts the development and maintenance of neurons in the peripheral nervous system and the functional integrity of neurons in the central nervous system [4]. For this reason, various preclinical characterizations and clinical trials with NGF have been performed [2]. In cases of clinical trials with recombinant human NGF (rhNGF) on peripheral neuropathies, phase I trials have shown that dose-dependent mild to moderate muscle pain and hyperalgesia appeared at the injection site as a side effect [5, 6]. Phase II trials of diabetic polyneuropathy indicate that rhNGF significantly improves the neuropathic symptoms, but produces dose-dependent hyperalgesia at the injection site [7, 8]. Other research has also demonstrated that although NGF develops and maintains the peripheral nervous system, it also contributes to producing hyperalgesia [9–11].

Although the evidence of neuropathic pain with NGF is obvious, there are still trials for NGF treatment because it has great pharmacological potential for the treatment of central neurodegenerative diseases and for peripheral neuropathies [2]. Interestingly, although it has been demonstrated that dose-dependent hyperalgesia is present at the injection site after a recombinant human NGF subcutaneous injection for peripheral neuropathies [8], there were no observable side effects when small amounts of NGF were injected through an intra-cerebro-ventricular channel for central nervous system diseases [12]. However, when injections of large amounts of NGF were administered, weight loss or back pain was reported even though it was administrated intra-cerebro-ventricularly [13]. Based on these results, we could understand that the route of injection and the amount of NGF being injected are important factors for the occurrence of neuropathic pain.

Hyperalgesia is a significant symptom for patients with neuropathic pain. Neuropathic pain is initiated or caused by a primary lesion to, or dysfunction in the nervous system [14]. Neuropathic pain and the dorsal root ganglion (DRG) are closely linked with each other. It is evident that hyperexcitability of DRG neurons is an important component for neuropathic pain [15]. The DRG neurons contain several kinds of peptides, which are related to various sensations [16]. Especially in the DRG, many small-diameter neurons are nociceptive and possess neuropeptides such as substance P (SP) and calcitonin gene-related peptide (CGRP), which are released in response to noxious simulation, are the main peptides for nociception [17]. It has been discovered that NGF-sensitive, tyrosine kinase receptor A (trkA) participates in pain processing and that neurons labeled with trkA overlap with neurons labeled with SP and CGRP [12, 13].

Sensory neuropathies, which is one of the peripheral neuropathies, are frequently associated with diabetes or anticancer therapies and less frequently associated with vitamin deficiency, hypothyroidism, uremia, and inherited metabolic disorders [18, 19]. Therefore, it is very important to develop animal models of sensory neuropathies. There are animal model studies using pyridoxine induced peripheral neuropathies [20, 21]. However these studies used extreme doses of pyridoxine or took a long period of time [22–24]. Chung et al. confirmed a dog model of sensory neuropathy by administering subcutaneous injections of pyridoxine over a short period of time [25]. This dog model fulfilled the requirement of advanced animal models with sensory neuropathies.

Based on these studies, we proposed a hypothesis that NGF gene therapy for pyridoxine induced neuropathy in dogs [26] could cause hyperalgesia. In this study, for identifying the relationship between NGF gene therapy and hyperalgesia, pain assessment including physical examination and electrophysiological recordings, and the changes in SP and CGRP levels were evaluated in dogs with pyridoxine-induced neuropathy that were administered NGF gene therapy.

Results

Pain assessment

Physical examination

The respiration rate (normal range 10–30 breaths/min), heart rate (normal range 70–180 breaths/min), rectal temperature (normal range 38.0–39.1 °C) and systolic arterial blood pressure (normal range 110–140 mmHg) of all three groups were within normal ranges during the experimental period (Fig. 1). However, weight measurements showed that there was significant weight loss only in the vehicle-treated group (p < 0.01), while there were no weight changes for the control group and the gene therapy group (Fig. 2).
Fig. 1
Fig. 1

The respiration rate, heart rate, rectal temperature and systolic arterial blood pressure of all three groups were within normal ranges during the experimental period without significantly changes. This results showed that there is no evidence of tachypnea, tachycardia, hypertension, and hyperthermia in all group, which are general physiological indicators of pain (n = 4 per group)

Fig. 2
Fig. 2

Body weight changes significantly only in the vehicle-treated group (p < 0.01) after pyridoxine treatment. This result evidences that NGF gene therapy in this study alleviated neuropathic pain, protecting the DRG from the neuropathic pain normally produced by pyridoxine (n = 4 per group)

Electrophysiological recording

Electrophysiological readings were recorded to measure M waves and H-reflexes in all groups before and after pyridoxine treatment. The M wave amplitude in all groups showed no remarkable change before and after the pyridoxine administration (p > 0.05). In the control group, H-reflexes did not change before or after pyridoxine injection. However, there was a remarkable change in the H-reflex before and after the pyridoxine treatment in the vehicle-treated group. Before pyridoxine injection, the average amplitude of the H-reflex was 0.52 ± 0.06 mV. After the pyridoxine injection, however, there was no consistently detectable H-reflex in the vehicle-treated group (p < 0.01). The H-reflexes in the NGF therapy group slightly decreased after pyridoxine injection, but significant differences were not detected before or after the pyridoxine injection (p > 0.05) (Fig. 3).
Fig. 3
Fig. 3

H-reflex disappears after the pyridoxine treatment in the vehicle-treated group (P < 0.01) however, H-reflexes do not change after the pyridoxine injection in the gene-treated group. This result evidences that NGF gene therapy in this study alleviated neuropathic pain (n = 4 per group)

Postural reaction assessments

On the postural reaction (hopping, wheelbarrowing, extensor postural thrust and proprioceptive positioning) assessment, all the dogs in the vehicle-treated group developed a neurological disorder, most prominently in the hindquarters. In addition, all dogs in this group started to show proprioceptive abnormalities involving their hindquarters as detected by the postural reaction test on the third day of the pyridoxine injections. These conditions were maintained until the end of the injections (p < 0.01). In contrast, all of the dogs in the control group and the gene therapy group were normal during the postural reaction test (Fig. 4).
Fig. 4
Fig. 4

On the postural reaction assessment, all the dogs only in the vehicle-treated group developed a neurological disorder, most prominently in the hindquarters on the third day of the pyridoxine injections. These conditions were maintained until the end of the injections. In contrast, all of the dogs in the control group and the gene therapy group were normal during the postural reaction test (n = 4 per group; **P < 0.01)

Histopathological analysis

Expression of NGF in the DRG

In the vehicle-treated group, NGF-positive neurons were barely detected in the DRG of L4, while in the pyridoxine-treated group, many NGF-positive neurons were detected in the DRG (Additional file 1: Figure S1).

Neuronal damage in the DRG

In the control group, cresyl violet positive neurons were abundantly detected in the DRG of L4 (Fig. 5a). In the vehicle-treated group, the presence of large-sized cresyl violet positive neurons was significantly decreased and those neurons were detected with vacuoles (Fig. 5b). In this group, the number of large-sized cresyl violet positive neurons was 51.7 % of the control group, while small- or medium-sized neurons were similarly detected compared to that in the control group (Fig. 5d). In the NGF therapy group, large-sized cresyl violet positive neurons were abundantly detected, although a few large vacuoles were also detected (Fig. 5c). In this group, the number of large-sized cresyl violet positive neurons was 78.1 % of the control group’s amount, while the number of medium- and small-sized neurons was not significantly different between them (Fig. 5d).
Fig. 5
Fig. 5

Cresyl violet staining of the dorsal root ganglion (DRG) in the control (a), vehicle-treated (Vehicle, b), and nerve growth factor gene-treated (NGF, c) groups at 4 weeks after pyridoxine injection for 1 week. In the control group, cresyl violet positive small- (white arrow), medium- (arrow head), and large-sized (black arrow) neurons are well detected in the DRG. Note that cresyl violet positive cells in the vehicle-treated group are few and some vacuoles are detected, while cresyl violet positive large-sized neurons are also abundant in the NGF group. Scale bar 100 μm. d Relative number as a % of small-, medium-, and large-sized neurons of the control group in the DRG (n = 4 per group; *P < 0.05, significantly different from the control group; # P < 0.05, significantly different from the vehicle group). The bars indicate the mean ± SEM

Immunoreactivity for SP and CGRP in the DRG

In the control group, SP immunoreactivity was mainly detected in the small- and medium-sized neurons, as well as the neuropil (Fig. 6a), while CGRP immunoreactivity was detected in all sized neurons (Fig. 6b). In the vehicle-treated group, the number of SP immunoreactive neurons was slightly decreased in the DRG compared to that in the control group, but the difference between the groups did not achieve significance (Fig. 6c, g). However, the number of CGRP immunoreactive small-, medium-, and large-sized neurons in the vehicle-treated group was significantly decreased compared to that in the control group (Fig. 6d, h). For the NGF-therapy group, SP immunoreactive neuron detection was similar to the vehicle-treated group (Fig. 6e, g). In contrast, the number of CGRP immunoreactive medium- and small-sized neurons was significantly greater in the DRG of the therapy group than that in the vehicle-treated group (Fig. 6f, h).
Fig. 6
Fig. 6

Substance P (SP) and calcitonin gene-related peptide (CGRP) immunostaining of the dorsal root ganglion (DRG) in the control (a, b), vehicle-treated (vehicle c, d), and nerve growth factor gene-treated (NGF e, f) groups at 4 weeks after 1 week of pyridoxine injection. In the control group, SP immunoreactive neurons are mainly detected in the small- and medium-sized neurons, while CGRP immunoreactive neurons in the small-, medium-, and large-sized neurons are well detected in the DRG. Number of SP immunoreactive neurons is similarly detected in all groups, while the number of CGRP immunoreactive neurons is decreased in the small- and medium-sized neurons of vehicle-treated group and this reduction is significantly ameliorated in the NGF group. Scale bar = 100 μm. g and h: Relative number as a % of small-, medium-, and large-sized neurons of the control group in the DRG (n = 4 per group; *P < 0.05, significantly different from the control group; # P < 0.05, significantly different from the vehicle group). The bars indicate the mean ± SEM

Discussion

A previous study found a protective effect of NGF gene therapy against pyridoxine induced sensory neuropathy in a dog model [26]. In this study, the characteristics of the pain induced by NGF gene therapy were evaluated in the same model. In the present study, we observed the significant reduction in the number of large-sized neurons in the DRG after pyridoxine intoxication. This result was supported by previous studies that the administration of pyridoxine selectively causes the damage in the large-diameter A-cells of the DRG with larger-diameter myelinated fibers in the sciatic nerve [20, 27, 28]. In our studies, we also observed the vulnerability of large-sized neurons after pyridoxine intoxication in DRG of dogs [25, 26, 29, 30].

The biological effects of neurotrophins are mediated via two major receptors, tyrosine kinase (Trk) receptors and 75 kDa (p75NTR). Each neurotrophin binds with high affinity to a specific Trk receptor. In the case of NGF, it has a high affinity to TrkA and a lower affinity to p75NTR [31]. Both NGF-trkA signaling and NGF-p75NTR participate in the neuropathic pain pathway [32]. NGF-trkA signaling dynamically regulates the synthesis of nociceptive neuropeptides like SP and CGRP, which contribute to the sensation of neuropathic pain [33]. For the relief of pain, there is critical need for drugs other than non-steroidal anti-inflammatory drugs. Based on these concepts, there are various trials of NGF antibody which sought to block the neuropathic pain, with the results indicating NGF antibody as s possible painkiller [29, 30].

For diagnosis and treatment of neuropathic pain, questionnaires to determine whether the symptoms indicate neuropathic pain or not are required, so many kinds of questionnaires have been developed for humans [34]. There are many trials for scaling pain in animals; however, there are not any special scales for neuropathic pain [35–37]. General physiological indicators of pain are tachypnea, tachycardia, hypertension, and hyperthermia. Additionally, anorexia resulting in weight loss is common in animals with significant acute or chronic pain [38]. In this study, there were no changes of respiratory rate, heart rate, body temperature or systolic arterial blood pressure in all three groups. However significant weight loss was confirmed only in the positive control group, not in the gene therapy group. This result evidences that NGF gene therapy in this study mitigated neuropathic pain, protecting the DRG from the neuropathic pain normally produced by pyridoxine. In this study, the route of the intrathecal region was chosen and the single dose of 40 μg NGF was used in the dog model. The dosage was decided by previous papers which used same manufactural cationic polymer transfection reagent to the intrathecal region [39, 40]. Based on the immunohistochemistry for NGF, we found that NGF effectively expressed in the DRG, which is the damaged area by pyridoxine. We could assume that the amount of NGF was not enough to cause neuropathic pain, but just enough to protect the DRG from the pyridoxine-induced neuropathy.

Unfortunately, though patients with neuropathic pain have the same predisposing condition, their responses to it could be varied [41]. For the objectification of analyzing neuropathic pain, the development of diagnostic techniques to identify it is necessary. There are a few trials to objectify the pain using the H-reflex. The muscle potential is the resultant activity of a true monosynaptic reflex arc and thus is appropriately referred to as an H-reflex. It has been demonstrated that a decrease in the mean H-reflex amplitude was observed in patients with back pain [42, 43]. Similarly to those studies, it was also confirmed that the H-reflex disappeared only in the positive control group in this study.

Forty percent of the DRG neurons are large-sized, which give rise to myelinated axons. In the present study, we observed a reduction in the number of large-sized neurons in the DRG after pyridoxine injection. This result was bolstered by our previous study where pyridoxine injection was found to significantly reduce the myelinated fibers in the sciatic nerve [25, 26]. NGF therapy is shown to significantly prevent the pyridoxine-induced decreases in the number of large-sized neurons in the DRG. The other 60 % of medium-/small sized neurons can be divided into neuropeptidergic and nonpeptidergic groups. The neuropeptidergic DRG neurons are easily detected by the CGRP antibody, comprising mostly small neurons with unmyelinated axons (C fibers) and innervating mainly polymodal nociceptors [44]. SP and CGRP are also expressed by a group of medium-sized cells with finely myelinated (Aδ) axons, most of which are nociceptors of the high-threshold mechanoreceptor type [44]. CGRP has important roles in trophic effects in the regeneration of peripheral nerves [45] except nociception. In this study, the significant reduction of CGRP may be associated with impairments of these trophic functions. This result was supported by previous study that the number of CGRP-positive neurons was significantly decreased in type 1 and 2 diabetic rats compared to their controls [46].

Conclusion

These results suggests that NGF gene therapy protects large-sized neurons from pyridoxine-induced injection and helps maintain tropic actions in the regeneration of peripheral nerves connected to DRG. With this study, we conclude that NGF gene therapy in pyridoxine induced neuropathic dogs does not induce neuropathic pain and facilitates the regeneration of pyridoxine-induced neuropathies in the DRG.

Methods

Animal model

Twelve dogs were used in this experiment, comprising 6 males and 6 females, each around 2 years of age. Their body weights ranged from 4 to 6 kg. All dogs were clinically judged to be in good health and neurologically normal. The handling and care of the animals was in compliance with current international laws and policies (NIH Guide for the Care and Use of Laboratory Animals, NIH Publication No. 85-23, 1985, revised 1996) and were approved by the Institutional Animal Care and Use Committee (IACUC) of Seoul National University (Approval no.: SNU-060623-1). Dogs were divided into 3 groups; control, vehicle-treated and gene therapy group (n = 4 in each group). To induce neuropathy, pyridoxine (Sigma, St. Louis, MO, USA) was prepared in physiological saline (100 mg/mL) immediately before injection, and administered at 150 mg/kg subcutaneously, once a day in the morning for 7 days [25] to the vehicle-treated and gene therapy groups.

Recombinant dog NGF gene therapy

Twenty-four hours before pyridoxine injection, all of the dogs were anesthetized with Zoletil 50® (Virbac, Carros, France). Thereafter, depending on the groups to which the dogs belonged, a 400 μL vehicle (cationic polymer transfection reagent, Polyplus transfection, France) or constructed recombinant dog NGF plasmid solution (40 μg/400 μL) was administered through the intrathecal region using a 27-gauge needle. The constructed recombinant dog NGF plasmid was established in the previous study [26].

Physical examination and postural reaction assessments

Physical examination including respiration rate (normal range 10–30 breaths/min), heart rate (normal range 70–180 beats/min), rectal temperature (normal range 38.0–39.1 °C), systolic arterial blood pressure (normal range: 110 mmHg -140 mmHg) and body weight of the test dogs were measured every morning during the test period. Postural reaction (hopping, wheelbarrowing, extensor postural thrust and proprioceptive positioning) assessments were also done on all dogs every morning during the test period (Table 1 in Appendix) [47].
Table 1

Postural reaction index

 

Front

Rear

Right

Left

Right

Left

Hopping

ⓞ①②③④

ⓞ①②③④

ⓞⓞ①②③④

ⓞ①②③④

Wheelbarrowing

ⓞ①②③④

ⓞ①②③④

  

Extensor postural thrust

  

ⓞ①②③④

ⓞ①②③④

Proprioceptive reaction

ⓞ①②③④

ⓞ①②③④

ⓞ①②③④

ⓞ①②③④

ⓞ Absent, ① Depressed, ② Normal, ③ Hyperactive, ④ Hyperactive with clonus

Electrophysiological recording

At 24 h after the last pyridoxine treatment, all dogs were preanesthetized with atropine (0.1 mg/kg of body weight, IM). Anesthesia was induced with diazepam and was maintained with isoflurane through a semi-closed system. Subcutaneous temperature was maintained at 37–38 °C and Neuropack2 (Nihon Kohden, Japan) was used for all recordings. All measurements were performed in the left hindlimb and M waves were recorded from the tibial nerve, using a 1 Hz, 0.5 ms, supramaximal stimulus. Stimulating electrodes were positioned at the distal tibial nerve and the recording electrode was positioned at the plantar interosseous muscle. The ground electrode was positioned between the stimulating electrode and the recording electrode. The recording electrode was a bipolar needle electrode. The Hoffman (H)-reflex was recorded using a 1 Hz, 0.5 ms, submaximal stimulus. The stimulating electrode was positioned at the tibial nerve adjacent to the hook, with the recording and ground electrodes positioned at the same sites of the tibial nerve where M waves were measured. All measurements were performed at least eight times. Electrophysiological recordings were performed twice, once before the experiment and once after the test period.

Tissue processing

For histological analysis, the dogs were anesthetized with a high dose of Zoletil 50® (Virbac, Carros, France) and propofol (Myungmoon Pharm., Seoul, Korea), and perfused transcardially with 0.1 M phosphate-buffered saline (PBS), followed by 4 % paraformaldehyde in 0.1 M PBS to induce euthanasia at 4 days after the last pyridoxine treatment. After perfusion, tissues from the left and right DRG of L4 were quickly removed and post-fixed for 24 h in the same fixative at 4 °C. They were then dehydrated with graded concentrations of alcohol before being embedded in paraffin. Paraffin-embedded tissues were serially sectioned using a microtome (Leica Microsystems GmbH, Wetzlar, Germany) into 3-μm sections, then were mounted onto silane-coated slides (Muto Pure Chemicals Co., Ltd, Tokyo, Japan). The sections apart from 150-μm each other were stained with cresyl violet according to the standard protocol.

Immunohistochemistry

The sections apart from 150-μm each other in all groups were hydrated and treated with 0.3 % hydrogen peroxide (H2O2) in PBS for 30 min. For antigen retrieval, the sections were placed in 400-mL jars filled with citrate buffer (pH 6.0) and heated in a microwave oven (Optiquick Compact, Moulinex) operating at a frequency of 2.45 GHz and an 800-W power setting. After three heating cycles of 5 min each, slides were allowed to cool to room temperature and were washed in PBS. After washing, the sections were incubated in 10 % normal goat serum in PBS for 30 min. They were then incubated with rabbit-NGF antibody (1:500; Biorbyt, San Francisco, CA, USA), rabbit anti-SP antibody (1:10,000; ImmunoStar, Hudson, WI, USA) or mouse-anti-CGRP (1:1,000; Abcam, Cambridge, UK) for 48 h at 4 °C. They were then exposed to either a biotinylated goat anti-rabbit IgG or anti-mouse IgG streptavidin peroxidase complex (diluted 1:200, Vector Laboratories, Inc., Burlingame, CA, USA), and visualized with 3,3ʹ-diaminobenzidine tetrahydrochloride (Sigma) in 0.1 M Tris–HCl buffer (pH 7.4).

The number of SP- or CGRP-immunoreactive neurons in each group of sections was counted in the DRGs using an image analyzing system equipped with a computer-based CCD camera (software: Optimas 6.5, CyberMetrics, Scottsdale, AZ, USA). DRG neurons were separated into three categories according to their sizes: small- (area 1000 μm2), medium- (area 1000–2000 μm2), and large-sized (>2000 μm2) neurons. The number of these neurons in all the groups was counted in the DRG using an image analyzing system equipped with a computer-based CCD camera (software: Optimas 6.5, CyberMetrics, Scottsdale, AZ). Cell counts were obtained by averaging the counts from DRG per section (10 sections) under a light microscope with a 10× lens.

Statistical analysis

A repeated measure one-way ANOVA test was done for the analysis of body weight measurements during the experimental period and a t test was done for the electrophysiological recordings and histochemical results before and after the pharmacologic treatment. The level of significance was set at p < 0.05.

Notes

Abbreviations

CGRP: 

calcitonin gene-related peptide

DRG: 

dorsal root ganglion

H reflex: 

Hoffman-reflex

NGF: 

nerve growth factor

rhNGF: 

recombinant human NGF

SP: 

substance P

trk: 

tyrosine kinase receptor

Declarations

Authors’ contributions

IH and JC designed the research, defined the intellectual content, edited the manuscript, and acted as guarantor for the entire experiment. MK JC, HY an SK edited the manuscript, and acted as guarantor for the entire experiment. JK and DY carried out the experiments and data analysis, and wrote the manuscript. KL and WI carried out the experiment and data analysis. All authors have read and approved the final manuscript.

Acknowledgements

This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2013R1A1A2059364, NRF-2014R1A1A1004339).

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Veterinary Internal Medicine and Geriatrics, College of Veterinary Medicine, Kangwon National University, Hyoja2-dong, Chuncheon-si, Gangwondo, 200-701, South Korea
(2)
Department of Anatomy and Cell Biology, College of Veterinary Medicine, and Research Institute for Veterinary Science, Seoul National University, Gwanak-ro 599, Gwanakgu, Seoul, 151-742, South Korea
(3)
Department of Anatomy, College of Veterinary Medicine, Kangwon National University, Hyoja2-dong, Chuncheon-si, Gangwondo, 200-701, South Korea
(4)
Department of Neurology and Protein Metabolism Medical Research Center, College of Medicine, Seoul National University Hospital, 101 Daehakro, Chongno-ku, Seoul, 110-744, South Korea
(5)
Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, Gwanak-ro 599, Gwanakgu, Seoul, 151-742, South Korea
(6)
Department of Orthopedic Surgery, College of Medicine, Seoul National University Hospital, 101 Daehakro, Chongno-ku, Seoul, 110-744, South Korea

References

  1. Bothwell M. NGF, BDNF, NT3, and NT4. Handb Exp Pharmacol. 2014;220:3–15.PubMedView ArticleGoogle Scholar
  2. Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med. 2012;10:239.PubMedPubMed CentralView ArticleGoogle Scholar
  3. Ebendal T. Function and evolution in the NGF family and its receptors. J Neurosci Res. 1992;32:461–70.PubMedView ArticleGoogle Scholar
  4. Aloe L, Bracci-Laudiero L, Bonini S, Manni L. The expanding role of nerve growth factor: from neurotrophic activity to immunologic diseases. Allergy. 1997;52:883–94.PubMedView ArticleGoogle Scholar
  5. Rogers BC. Development of recombinant human nerve growth factor (rhNGF) as a treatment for peripheral neuropathic disease. Neurotoxicology. 1996;17:865–70.PubMedGoogle Scholar
  6. Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, Sinicropi D, Burton LE, Peroutka SJ. The effect of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol. 1994;36:244–6.PubMedView ArticleGoogle Scholar
  7. Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology. 1998;51:695–702.PubMedView ArticleGoogle Scholar
  8. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol. 2002;50:393–413.PubMedView ArticleGoogle Scholar
  9. Diamond J, Holmes M, Coughlin M. Endogenous NGF and nerve impulses regulate the collateral sprouting of sensory axons in the skin of the adult rat. J Neurosci. 1992;12:1454–66.PubMedGoogle Scholar
  10. Pertens E, Urschel-Gysbers BA, Holmes M, Pal R, Foerster A, Kril Y, Diamond J. Intraspinal and behavioral consequences of nerve growth factor-induced nociceptive sprouting and nerve growth factor-induced hyperalgesia compared in adult rats. J Comp Neurol. 1999;410:73–89.PubMedView ArticleGoogle Scholar
  11. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci. 1994;6:1903–12.PubMedView ArticleGoogle Scholar
  12. McArthur JC, Yiannoutsos C, Simpson DM, Adornato BT, Singer EJ, Hollander H, Marra C, Rubin M, Cohen BA, Tucker T, et al. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology. 2000;54:1080–8.PubMedView ArticleGoogle Scholar
  13. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, Olson L, Seiger, Shigeta M, Theodorsson E, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer’s disease. Dement Geriatr Cogn Disord. 1998;9:246–57.Google Scholar
  14. Jensen TS, Finnerup NB. Allodynia and hyperalgesia in neuropathic pain: clinical manifestations and mechanisms. Lancet Neurol. 2014;13:924–35.PubMedView ArticleGoogle Scholar
  15. Chung JM, Chung K. Importance of hyperexcitability of DRG neurons in neuropathic pain. Pain Pract. 2002;2:87–97.PubMedView ArticleGoogle Scholar
  16. Lallemend F, Ernfors P. Molecular interactions underlying the specification of sensory neurons. Trends Neurosci. 2012;35:373–81.PubMedView ArticleGoogle Scholar
  17. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature. 2001;413:203–10.PubMedView ArticleGoogle Scholar
  18. Callizot N, Warter JM, Poindron P. Pyridoxine-induced neuropathy in rats: a sensory neuropathy that responds to 4-methylcatechol. Neurobiol Dis. 2001;8:626–35.PubMedView ArticleGoogle Scholar
  19. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994;35:304–11.PubMedView ArticleGoogle Scholar
  20. Perry TA, Weerasuriya A, Mouton PR, Holloway HW, Greig NH. Pyridoxine-induced toxicity in rats: a stereological quantification of the sensory neuropathy. Exp Neurol. 2004;190:133–44.PubMedView ArticleGoogle Scholar
  21. Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand. 1987;76:8–11.PubMedView ArticleGoogle Scholar
  22. Hoover DM, Carlton WW. The subacute neurotoxicity of excess pyridoxine HCl and clioquinol (5-chloro-7-iodo-8-hydroxyquinoline) in beagle dogs. II. Pathology. Vet Pathol. 1981;18:757–68.PubMedView ArticleGoogle Scholar
  23. Krinke GJ, Fitzgerald RE. The pattern of pyridoxine-induced lesion: difference between the high and the low toxic level. Toxicology. 1988;49:171–8.PubMedView ArticleGoogle Scholar
  24. Krinke G, Naylor DC, Skorpil V. Pyridoxine megavitaminosis: an analysis of the early changes induced with massive doses of vitamin B6 in rat primary sensory neurons. J Neuropathol Exp Neurol. 1985;44:117–29.PubMedView ArticleGoogle Scholar
  25. Chung JY, Choi JH, Hwang CY, Youn HY. Pyridoxine induced neuropathy by subcutaneous administration in dogs. J Vet Sci. 2008;9:127–31.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Chung JY, Choi JH, Shin IS, Choi EW, Hwang CY, Lee SK, Youn HY. In vitro and in vivo gene therapy with CMV vector-mediated presumed dog beta-nerve growth factor in pyridoxine-induced neuropathy dogs. J Vet Sci. 2008;9:367–73.PubMedPubMed CentralView ArticleGoogle Scholar
  27. Schaeppi U, Krinke G. Pyridoxine neuropathy: correlation of functional tests and neuropathology in beagle dogs treated with large doses of vitamin B6. Agents Actions. 1982;12:575–82.PubMedView ArticleGoogle Scholar
  28. Albin RL, Albers JW, Greenberg HS, Townsend JB, Lynn RB, Burke JM Jr, Alessi AG. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology. 1987;37:1729–32.PubMedView ArticleGoogle Scholar
  29. Rapp AE, Kroner J, Baur S, Schmid F, Walmsley A, Mottl H, Ignatius A. Analgesia via blockade of NGF/TrkA signaling does not influence fracture healing in mice. J Orthop Res. 2015;33:1235–41.PubMedView ArticleGoogle Scholar
  30. Lascelles BD, Knazovicky D, Case B, Freire M, Innes JF, Drew AC, Gearing DP. A canine-specific anti-nerve growth factor antibody alleviates pain and improves mobility and function in dogs with degenerative joint disease-associated pain. BMC Vet Res. 2015;11:101.PubMedPubMed CentralView ArticleGoogle Scholar
  31. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurobiol. 2001;11:272–80.PubMedView ArticleGoogle Scholar
  32. Khan N, Smith MT. Neurotrophins and neuropathic pain: role in pathobiology. Molecules. 2015;20:10657–88.PubMedView ArticleGoogle Scholar
  33. Shadiack AM, Sun Y, Zigmond RE. Nerve growth factor antiserum induces axotomy-like changes in neuropeptide expression in intact sympathetic and sensory neurons. J Neurosci. 2001;21:363–71.PubMedGoogle Scholar
  34. Benzon HT. The neuropathic pain scales. Reg Anesth Pain Med. 2005;30:417–21.PubMedView ArticleGoogle Scholar
  35. Anil SS, Anil L, Deen J. Challenges of pain assessment in domestic animals. J Am Vet Med Assoc. 2002;220:313–9.PubMedView ArticleGoogle Scholar
  36. Hansen BD. Assessment of pain in dogs: veterinary clinical studies. ILAR J. 2003;44:197–205.PubMedView ArticleGoogle Scholar
  37. Brown DC, Boston RC, Coyne JC, Farrar JT. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc. 2008;233:1278–83.PubMedPubMed CentralView ArticleGoogle Scholar
  38. Gaynor JS, Muir WW. Handbook of veterinary pain management, 3rd edn. St. Louis, Missouri: Elsevier; 2015.Google Scholar
  39. Liu S, Yang J, Wang L, Jiang M, Qiu Q, Ma Z, Liu L, Li C, Ren C, Zhou J, et al. Tibia tumor-induced cancer pain involves spinal p38 mitogen-activated protein kinase activation via TLR4-dependent mechanisms. Brain Res. 2010;1346:213–23.PubMedView ArticleGoogle Scholar
  40. Jin XH, Wang LN, Zuo JL, Yang JP, Liu SL. P2X4 receptor in the dorsal horn partially contributes to brain-derived neurotrophic factor oversecretion and toll-like receptor-4 receptor activation associated with bone cancer pain. J Neurosci Res. 2014;92:1690–702.PubMedView ArticleGoogle Scholar
  41. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32.PubMedPubMed CentralView ArticleGoogle Scholar
  42. Ginanneschi F, Dominici F, Milani P, Biasella A, Rossi A, Mazzocchio R. Changes in the recruitment curve of the soleus H-reflex associated with chronic low back pain. Clin Neurophysiol. 2007;118:111–8.PubMedView ArticleGoogle Scholar
  43. Mazzocchio R, Scarfo GB, Mariottini A, Muzii VF, Palma L. Recruitment curve of the soleus H-reflex in chronic back pain and lumbosacral radiculopathy. BMC Musculoskelet Disord. 2001;2:4.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Priestley JV, Michael GJ, Averill S, Liu M, Willmott N. Regulation of nociceptive neurons by nerve growth factor and glial cell line derived neurotrophic factor. Can J Physiol Pharmacol. 2002;80:495–505.PubMedView ArticleGoogle Scholar
  45. Dumoulin FL, Raivich G, Haas CA, Lazar P, Reddington M, Streit WJ, Kreutzberg GW. Calcitonin gene-related peptide and peripheral nerve regeneration. Ann N Y Acad Sci. 1992;657:351–60.PubMedView ArticleGoogle Scholar
  46. Adeghate E, Rashed H, Rajbandari S, Singh J. Pattern of distribution of calcitonin gene-related peptide in the dorsal root ganglion of animal models of diabetes mellitus. Ann N Y Acad Sci. 2006;1084:296–303.PubMedView ArticleGoogle Scholar
  47. Oliver JE, Lorenz MD, Kornegay JN. Handbook of veterinary neurology. 3rd ed. Philadelphia: W.B. Saunders; 1997.Google Scholar

Copyright

© Kang et al. 2016

Advertisement

BMC Neuroscience

ISSN: 1471-2202

Contact us